2. Wigley F.M., Flavahan N.A. Raynaud’s phenomenon. N Engl J Med. 2016; 375(6): 556–65.

https://doi.org/10.1056/nejmra1507638. PMID: 27509103.

3. Susol E. Genetic investigation of primary Raynaud’s phenomenon and systemic sclerosis. Manchester: The University of Manchester. 1999.

4. Goldman R.D. Raynaud phenomenon in children. Can Fam Physician. 2019; 65(4): 264–65. PMID: 30979757. PMCID: PMC6467660.

5. Klein-Weigel P., Sander O., Reinhold S. et al. Raynaud’s phenomenon: A vascular acrosyndrome that requires long-term care. Dtsch Arztebl Int. 2021; 118(Forthcoming): 273–80.

https://doi.org/10.3238/arztebl.m2021.0023. PMID: 33632387. PMCID: PMC8287761.

6. Casanegra A.I., Shepherd R.F. Raynaud phenomenon and other vasospastic disorders. Cardiol Сlin. 2021; 39(4): 583–99.

https://doi.org/10.1016/j.ccl.2021.06.010. PMID: 34686269.

7. Haque A., Hughes M. Raynaud’s phenomenon. Clin Med (Lond). 2020; 20(6): 580–87.

https://doi.org/10.7861/clinmed.2020-0754. PMID: 33199324. PMCID: PMC7687329.

8. Devgire V., Hughes M. Raynaud’s phenomenon. Br J Hosp Med (Lond). 2019; 80: 658–64.

https://doi.org/10.12968/hmed.2019.80.11.658. PMID: 31707892.

9. Wigley F.M., Herrick A.L., Flavahan N.A. (eds.). Raynaud’s phenomenon: A Guide to pathogenesis and treatment. New York: Springer New York. 2015; 394 pp.

https://doi.org/10.1007/978-1-4939-1526-2. ISBN: 978-1-4939-4724-9.

10. Garner R., Kumari R., Lanyon P. et al. Prevalence, risk factors and associations of primary Raynaud’s phenomenon: Systematic review and meta-analysis of observational studies. BMJ Open. 2015; 5(3): e006389.

https://doi.org/10.1136/bmjopen-2014-006389. PMID: 25776043. PMCID: PMC4368987.

11. Belch J., Carlizza A., Carpentier P.H. et al. ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon. Vasa. 2017; 46(6): 413–23.

https://doi.org/10.1024/0301-1526/a000661. PMID: 28895508.

12. Frech T., Khanna D., Markewitz B. et al. Heritability of vasculopathy, autoimmune diseases, and fibrosis: A population-based study. Arthritis Rheum. 2010; 62(7): 2109–16.

https://doi.org/10.1002/art.27469. PMID: 20506251. PMCID: PMC2956122.

13. Cordeiro R.A., de Andrade R.M. Raynaud’s phenomenon in the occupational context. Rev Assoc Med Bras (1992). 2019; 65(10): 1314–20.

https://doi.org/10.1590/1806-9282.65.10.1314. PMID: 31721965.

14. Herrick A.L. Raynaud’s phenomenon. J Scleroderma Relat Disord. 2019; 4(2): 89–101.

https://doi.org/10.1177/2397198319826467. PMID: 35382391. PMCID: PMC8922643.

15. Gayraud M. Raynaud’s phenomenon. Joint Bone Spine. 2007; 74(1): e1–8.

https://doi.org/10.1016/j.jbspin.2006.07.002. PMID: 17218139.

16. Duquene P.P., Pistorius M.A., Pottier P. et al. Cold climate could be an etiologic factor involved in Raynaud’s phenomenon physiopathology. Epidemiological investigation from 954 consultations in general practic. Int Angiol. 2015; 34(5): 467–474. PMID:25394956.

17. Schneeberger D., Tyndall A., Kay J. et al. Systemic sclerosis without antinuclear antibodies or Raynaud’s phenomenon: A multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford). 2013; 52(3): 560–67.

https://doi.org/10.1093/rheumatology/kes315. PMID: 23221323.

18. Алекперов Р.Т., Старовойтова М.Н. Синдром Рейно в практике терапевта. РМЖ. 2010; 18(27): 1695–1700. (Alekperov R.T., Starovoitova M.N. Raynaud’s syndrome in the practice of a therapist. Rossiyskiy meditsinskiy zhurnal = Russian Medical Journal. 2010; 18(27): 1695–1700 (In Russ.)). EDN: PYRKYJ.

19. Bakst R., Merola J.F., Franks A.G. Jr., Sanchez M. Raynaud’s phenomenon: Pathogenesis and management. J Am Acad Dermatol. 2008; 59(4): 633–53.

https://doi.org/10.1016/j.jaad.2008.06.004. PMID: 18656283.

20. Kaheleh B., Matucci-Cerinic M. Raynaud’s phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum. 1995; 38(1): 1–4.

https://doi.org/10.1002/art.1780380102. PMID: 7818557.

21. Furspan P.B., Chatterjee S., Freedman R.R. Increased tyrosine phosphorylation mediates the cooling–induced contraction and increased vascular reactivity of Raynaud’s disease. Arthritis Rheum. 2004; 50(5): 1578–85.

https://doi.org/10.1002/art.20214. PMID: 15146428.

22. Cooke J.P., Marshall J.M. Mechanisms of Raynaud’s disease. Vasc Med. 2005; 10(4): 293–307.

https://doi.org/10.1191/1358863x05vm639ra. PMID: 1644485.

23. Herrick A.L., Rieley F., Schofield D. et al. Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol. 1994; 21(8): 1477–83. PMID: 7983650.

24. Goyle K.B., Dormandy J.A. Abnormal blood viscosity in Raynaud’s phenomenon. Lancet. 1976; 1(7973): 1317–18.

https://doi.org/10.1016/s0140-6736(76)92651-9. PMID: 58309.

25. Temprano K.K. A review of Raynaud’s disease. Mo Med. 2016; 113(2): 123–26. PMID: 27311222. PMCID: PMC6139949.

26. Maverakis E., Patel F., Kronenberg D.G. et al. International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun. 2014; 48–49: 60–65.

https://doi.org/10.1016/j.jaut.2014.01.020. PMID: 24491823. PMCID: PMC4018202.

27. Voulgari P.V., Alamanos Y., Papazisi D. et al. Prevalence of Raynaud’s phenomenon in a healthy Greek population. Ann Rheum Dis. 2000; 59(3): 206–10.

https://doi.org/10.1136/ard.59.3.206. PMID: 10700429. PMCID: PMC1753096.

28. Ingegnoli F., Gualtierotti R., Orenti A. et al. Uniphasic blanching of the fingers, abnormal capillaroscopy in nonsymptomatic digits, and autoantibodies: Expanding options to increase the level of suspicion of connective tissue diseases beyond the classification of Raynaud’s phenomenon. J Immunol Res. 2015; 2015: 371960.

https://doi.org/10.1155/2015/371960. PMID: 26075287. PMCID: PMC4449942.

29. Pauling J.D., Reilly E., Smith T., Frech T.M. Evolving symptom characteristics of Raynaud’s phenomenon in systemic sclerosis and association with physician and patient-reported assessment of disease severity. Arthritis Care Res (Hoboken). 2019; 71(8): 1119–26.

https://doi.org/10.1002/acr.23729. PMID: 30133174.

30. Pauling J.D., Hughes M., Pope J.E. Raynaud’s phenomenon-an update on diagnosis, classification and management. Clin Rheumatol. 2019; 38(12): 3317–30.

https://doi.org/10.1007/s10067-019-04745-5. PMID: 31420815.

31. O’Connor C.M. Raynaud’s phenomenon. J Vasc Nurs. 2001; 19(3): 87–92.

https://doi.org/10.1067/mvn.2001.117786. PMID: 11533581.

32. Гайсин И.Р., Багаутдинова З.Р. Современные тенденции в определении и лечении феномена Рейно. Лечащий врач. 2019; (2): 38. (Gaysin I.R., Bagautdinova Z.R. Current trends in the definition and treatment of Raynaud’s phenomenon. Lechaschiy vrach = Attending Physician. 2019; (2): 38 (In Russ.)). EDN: ATZFAL.

33. Алекперов Р.Т. Синдром Рейно как мультидисциплинарная проблема. Альманах клинической медицины. 2014; (35): 94–100. (Alekperov R.T. Raynaud’s phenomenon: A multidisciplinary problem. Al’manakh klinicheskoy meditsiny = Almanac of Clinical Medicine. 2014; (35): 94–100 (In Russ.)). EDN: TFKLYP.

34. Ананьева Л.П. Ранняя системная склеродермия – современный алгоритм диагностики (лекция). Научно-практическая ревматология. 2012; 50(2): 87–93. (Ananyeva L.P. Early systemic scleroderma: A current diagnostic algorithm (a lecture). Nauchcno-practicheskaya revmatologiya = Rheumatology Science and Practice. 2012; 50(2): 87–93 (In Russ.)). EDN: OYLRFN.

35. Sharp C.A., Akram Q., Hughes M. et al. Differential diagnosis of critical digital ischemia in systemic sclerosis: Report of five cases and review of the literature. Semin Arthritis Rheum. 2016; 46(2): 209–16.

https://doi.org/10.1016/j.semarthrit.2016.05.001. PMID: 27318627.

36. Hughes M., Allanore Y., Chung L. et al. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol. 2020; 16(4): 208–21.

https://doi.org/10.1038/s41584-020-0386-4. PMID: 32099191.

37. Hughes M., Ong V.H., Anderson M.E. et al. Consensus best practice pathway of the UK Scleroderma Study Group: Digital vasculopathy in systemic sclerosis. Rheumatology (Oxford). 2015; 54(11): 2015–24.

https://doi.org/10.1093/rheumatology/kev201. PMID: 2611615.

38. Herrick A.L., Dinsdale G., Murray A. Eur. New perspectives in the imaging of Raynaud’s phenomenon. Eur J Rheumatol. 2020; 7(Suppl 3): S212–S221.

https://doi.org/10.5152/eurjrheum.2020.19124. PMID: 33164735. PMCID: PMC7647685.

39. Deak Z., Treitl M., Reiser M.F., Degenhart C. Angiographic diagnosis of acral circulatory disorders of the upper extremities. Radiologe. 2010; 50(10): 879–86.

https://doi.org/10.1007/s00117-010-2005-x. PMID: 20824423.

40. Connell D.A., Koulouris G., Thorn D.A., Potter H.G. Contrast-enhanced MR angiography of the hand. Radiographics. 2002; 22(3): 583–99.

https://doi.org/10.1148/radiographics.22.3.g02ma16583. PMID: 12006689.

41. Алекперов Р.Т. Капилляроскопия в диагностике синдрома Рейно и системной склеродермии. Научно-практическая ревматология. 2008; 46(S 3): 31–34. (Alekperov R.T. Capillaroscopy in the diagnosis of Raynaud’s syndrome and systemic scleroderma. Nauchcno-practicheskaya revmatologiya = Rheumatology Science and Practice. 2008; 46(S 3): 31–34 (In Russ.)). EDN: QINXWR.

42. Smith V., Beeckman S., Herrick A.L. et al. An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology (Oxford). 2016; 55(5): 883–90.

https://doi.org/10.1093/rheumatology/kev441. PMID: 26843483.

43. Ананьева Л.П. Лечение системной склеродермии с учетом национальных рекомендаций и рекомендаций Европейской лиги по борьбе с ревматизмом (EULAR). Фарматека. 2014; (10): 79–86. (Ananyeva L.P. Treatment of systemic scleroderma based on national recommendations and recommendations of the European League against Rheumatism (EULAR). Farmateka. 2014; (10): 79–86 (In Russ.)). EDN: SLSVGP.

44. Stewart M., Morling J.R. Oral vasodilators for primary Raynaud’s phenomenon. Cochrane Database Syst Rev. 2012; 2012(7): CD006687.

https://doi.org/10.1002/14651858.cd006687.pub3. PMID: 22786498. PMCID: PMC6718219.

45. Алекперов Р.Т. Синдром Рейно в практике ревматолога. Современная ревматология. 2014; 8(2): 37–46. (Alekperov R.T. Raynaud’s phenomenon in the rheumatologist’s practice. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014; 8(2): 37–46 (In Russ.)). EDN: SEUMPP.

46. Kowal-Bielecka O., Landewe R., Avouac J. et al.; EUSTAR Co-Authors EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68(5): 620–28.

https://doi.org/10.1136/ard.2008.096677. PMID: 19147617.

47. Kowal-Bielecka O., Fransen J., Avouac J. et al.; EUSTAR Coauthors Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017; 76(8): 1327–39.

https://doi.org/10.1136/annrheumdis-2016-209909. PMID: 27941129.

48. Roustit M., Blaise S., Allanore Y. et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: Systematic review and metaanalysis of randomised trials. Ann Rheum Dis. 2013; 72(10): 1696–99.

https://doi.org/10.1136/annrheumdis2012-202836. PMID: 23426043.

49. Shenoy P.D., Kumar S., Jha L.K. et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: A double-blind randomized cross-over trial. Rheumatology (Oxford). 2010; 49(12): 2420–28.

https://doi.org/10.1093/rheumatology/keq291. PMID: 20837499.

50. Schiopu E., Hsu V.M., Impens A.J. et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009; 36(10): 2264–68.

https://doi.org/10.3899/jrheum.090270. PMID: 19755613.

51. Herrick A.L., ven den Hoogen F., Gabrielli A. et al. Modified-release sildenafil reduces Raynaud’s attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011; 63(3): 775–82.

https://doi.org/10.1002/art.30195. PMID: 21360507.

52. Tingey T., Shu J., Smuczek J., Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken). 2013; 65(9): 1460–71.

https://doi.org/10.1002/acr. 22018. PMID: 23554239.

53. Российские клинические рекомендации. Ревматология. Под ред. академика РАН Е.Л. Насонова. М.: ГЭОТАР-Медиа. 2017; 464 с. (Russian clinical guidelines. Rheumatology. Ed. by academician of RAS Nasonov E.L. Moscow: GEOTAR-Media. 2017; 464 pp. (In Russ.)). ISBN: 978-5-9704-4261-6.

54. Wigley F.M., Seibold J.R., Wise R.A. et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol. 1992; 19(9): 1407–14. PMID: 1279170.

55. Wigley F.M., Wise R.A., Seibold J.R. et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebocontrolled, double-blind study. Ann Intern Med. 1999; 120(3): 199–206.

https://doi.org/10.7326/0003-4819-120-3-199402010-00004. PMID: 7506013.

56. Pope J., Fenlon D., Thompson A. et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst. Rev. 2000; 1998(2): CD000953.

https://doi.org/10.1002/14651858.CD000953. PMID: 10796395. PMCID: PMC7032888.

57. Ingegnoli F., Schioppo T., Allanore Y. et al. Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Semin Arthritis Rheum. 2019; 48(4): 686–93.

https://doi.org/10.1016/j.semarthrit.2018.03.019. PMID: 29706243.

58. Marasini B., Massarotti M., Bottasso B. et al. Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004; 33(4): 253–56.

https://doi.org/10.1080/03009740310004711. PMID: 15370722.

59. Korn J.H., Mayes M., Cerinic M.M. et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004; 50(12): 3985–93.

https://doi.org/10.1002/art.20676. PMID: 15593188.

60. Matucci-Cerinic M., Denton C.P., Furst D.E. et al. Bosentan treatment of digital ulcers related to systemic sclerosis: Results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011; 70(1): 32–38.

https://doi.org/10.1136/ard. 2010.130658. PMID: 20805294. PMCID: PMC3002766.

61. Baumhakel M., Böhm M. Recent achievements in the management of Raynaud’s phenomenon. Vasc Health Risk Manag. 2010; 6: 207–14.

https://doi.org/10.2147/vhrm.s5255. PMID: 20407628. PMCID: PMC2856576.

62. Curtiss P., Schwager Z., Cobos G. et al. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol. 2018; 78(6): 1110–1118.e3.

https://doi.org/10.1016/j.jaad.2018.01.043. PMID: 29408338.

63. Dziadzio M., Denton C.P., Smith R. et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999; 42(12): 2646–55.

https://doi.org/10.1002/1529-0131(199912)42:12%3C2646::aid-anr21%3E3.0.co;2-t. PMID: 10616013.

64. van der Meer J., Wouda A.A., Kallenberg C.G., Wesseling H. A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud’s phenomenon. Vasa Suppl. 1987; 18: 71–75. PMID: 3299819.

65. Abou-Raya A., Abou-Raya S., Helmii M. Statins: Potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008; 35(9): 1801–8. PMID: 18709692.

66. Coleiro B., Marshall S.E., Denton C.P. et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001; 40(9): 1038–43.

https://doi.org/10.1093/rheumatology/40.9.1038. PMID: 11561116.

67. Wasserman A., Brahn E. Systemic sclerosis: Bilateral improvement of Raynaud’s phenomenon with unilateral digital sympathectomy. Semin Arthritis Rheum. 2010; 40(2): 137–46.

https://doi.org/10.1016/j.semarthrit.2009.08.002. PMID: 19878974.

68. Bank J., Fuller S.M., Henry G.I., Zachary L.S. Fat grafting to the hand in patients with Raynaud phenomenon: A novel therapeutic modality. Plast Reconstr Surg. 2014; 133(5): 1109–18.

https://doi.org/10.1097/PRS.0000000000000104. PMID: 24445877.

69. Motegi S.-I., Uehara A., Yamada K. et al. Efficacy of botulinum toxin B injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis. Acta Derm Venereol. 2017; 97(7): 843–50.

https://doi.org/10.2340/00015555-2665. PMID: 28358168.

70. Bello R.J., Cooney C.M., Melamed E. et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud’s phenomenon: A randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017; 69(8): 1661–69.

https://doi.org/10.1002/art.40123. PMID: 28426903. PMCID: PMC5529251.